The key companies such as Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others are involved in developing drugs for Non-Alcoholic Steatohepatitis.
The Non-Alcoholic Steatohepatitis report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The report also highlights the unmet needs concerning the development of Non-Alcoholic Steatohepatitis.
Some of the key highlights of the Non-Alcoholic Steatohepatitis Pipeline Report–
- Resmetirom (MGL-3196) is a first-in-class, orally-administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist.
- 348 patients were screened and 84 were randomly assigned to resmethrin and 41 to placebo at 18 sites in the USA.
- Key Players Involved in the Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others.
Request for Sample @ Non-Alcoholic Steatohepatitis Pipeline Insights
Non-Alcoholic Steatohepatitis Overview
Non-Alcoholic Steatohepatitis, liver inflammation, and damage caused by a buildup of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions. The more severe form of NAFLD is called nonalcoholic steatohepatitis (NASH).
NASH Emerging Therapy: Drug Profile
MGL-3196: Madrigal Pharmaceuticals
Resmetirom neither suppresses the central thyroid axis nor THR-α effects on heart rate or bone, and it reduces elevated liver enzymes in NASH patients. Madrigal Pharmaceuticals plans to submit a marketing approval application in Non-alcoholic steatohepatitis to the US FDA.
Know More Information @ NASH Pipeline Drugs
Key Pipeline Therapies along with companies
- MGL-3196: Madrigal Pharmaceuticals
- Oltipraz: Pharmaking
- TERN-101:Terns Pharmaceuticals
- EYP001: ENYO Pharma
- ZSP-1601: Guangdong Zhongsheng Pharmaceutical
- ALN-HSD: Alnylam Pharmaceuticals
- AZF-2693: AstraZeneca
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Intravenous
- Inhalation
- Oral
- Subcutaneous
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
By Mechanism of Action
- Protease Inhibitors
- Immunomodulatory
By Targets
- Protease
- Immune System
Contact Here for More Information @ NASH Pipeline Assessment
Scope of NASH Pipeline Report
- Coverage- Global
- Key Market Players-Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others.
- Key NASH Pipeline Therapies- MGL-3196, Oltipraz, TERN-101, EYP001, ZSP-1601, ALN-HSD, AZF-2693, and many others
Following is the Table of Content of the NASH Pipeline Report
| 1 | Report Introduction |
| 2 | Non-Alcoholic Steatohepatitis (NASH) |
| 3 | Non-Alcoholic Steatohepatitis (NASH) Current Treatment Patterns |
| 4 | Non-Alcoholic Steatohepatitis (NASH) – DelveInsight’s Analytical Perspective |
| 5 | Therapeutic Assessment |
| 6 | Non-Alcoholic Steatohepatitis (NASH) Late Stage Products (Phase-III) |
| 7 | Non-Alcoholic Steatohepatitis (NASH) Mid Stage Products (Phase-II) |
| 8 | Early Stage Products (Phase-I) |
| 9 | Pre-clinical Products and Discovery Stage Products |
| 10 | Inactive Products |
| 11 | Dormant Products |
| 12 | Non-Alcoholic Steatohepatitis (NASH) Discontinued Products |
| 13 | Non-Alcoholic Steatohepatitis (NASH) Product Profiles |
| 14 | Non-Alcoholic Steatohepatitis (NASH) Key Companies |
| 15 | Non-Alcoholic Steatohepatitis (NASH) Key Products |
| 16 | Dormant and Discontinued Products |
| 17 | Non-Alcoholic Steatohepatitis (NASH) Unmet Needs |
| 18 | Non-Alcoholic Steatohepatitis (NASH) Future Perspectives |
| 19 | Non-Alcoholic Steatohepatitis (NASH) Analyst Review |
| 20 | Appendix |
| 21 | Report Methodology |
Know more of what’s covered in the NASH Pipeline Assessment report
Key Questions Answered in the NASH report–
- What are the current options for Non-Alcoholic Steatohepatitis (NASH) treatment?
- How many companies are developing therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
- How many Non-Alcoholic Steatohepatitis (NASH) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Non-Alcoholic Steatohepatitis (NASH) market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Non-Alcoholic Steatohepatitis (NASH) therapies?
- What are the clinical studies going on for Non-Alcoholic Steatohepatitis (NASH) and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Non-Alcoholic Steatohepatitis (NASH)?
- How many patents are granted and pending for the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
Request for demo @ NASH Pipeline and get a walk-through of our report
Related Reports
DelveInsight’ s Uncontrolled Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.
Post-Operative Nausea & Vomiting Market
DelveInsight’ s Postoperative Nausea & Vomiting Market Insights, Epidemiology and Market Forecast – 2030 report.
Heavy Menstrual Bleeding Market
DelveInsight’ s Heavy Menstrual Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.
Visit on our blog section-
- Bleeding Disorders Therapeutics Market
- Gastroparesis Market Size | Gastroparesis Market | DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Shruti Thakur info@delveinsight.com
Tags:
, Menafn, IPS, Reportedtimes, PR-Wirein, Extended Distribution, iCN Internal Distribution, Research Newswire, English
Contact Information:
Shruti Thakur
info@delveinsight.com
The post Non-Alcoholic Steatohepatitis Pipeline Analysis: Overview, Pipeline Drugs, and Therapeutics Assessment appeared first on Financial Market Brief.
